SCHEMBL9212663

SCHEMBL9212663

CCCCc1cn(C2CCCCC2CCC)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)nc1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 15/20 0.59
AGTR2 P50052 13/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9278990 0.99 AGTR1 (0.58) AGTR1AGTR2
SCHEMBL9272080 0.98 AGTR1 (0.61) AGTR1AGTR2
SCHEMBL9275056 0.95 AGTR1 (0.60) AGTR1AGTR2
SCHEMBL9271314 0.94 AGTR1 (0.59) AGTR1AGTR2
SCHEMBL9276974 0.93 AGTR1 (0.62) AGTR1AGTR2
SCHEMBL9274124 0.92 AGTR1 (0.66) AGTR1AGTR2
SCHEMBL7675463 0.92 AGTR1 (0.63) AGTR1AGTR2
SCHEMBL9208144 0.91 AGTR1 (0.59) AGTR1AGTR2
SCHEMBL9274390 0.91 AGTR1 (0.65) AGTR1AGTR2
SCHEMBL9209240 0.91 AGTR1 (0.62) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0664803-A1 N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1995-08-02 EP claimed
WO-1994008989-A1 N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-04-28 WO claimed
EP-0664803-A1 N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1995-08-02 EP disclosed
WO-1994008989-A1 N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-04-28 WO disclosed